Karen Pet

AccelRx Research

Fall River, Massachusetts - 02721 (508-675-1411)

CLINICAL TRIALS 1
CONDITIONS4
INTERVENTIONS2
SINCE2009

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

October 2009 - November 2010

Depression

Depressive Disorder

Depressive Disorder, Major

Recurrence

Matching Placebo

Spd489 (Lisdexamfetamine Dimesylate)

Learn about TrialX Patient Recruitment services

Massimo Loda, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Suzanne Shusterman

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Childrens Hospital Boston, Dana-Farber Cancer Institute. Children's Hospital Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute Dana Farber / Brigham and Women's Cancer Center Dana-Farber Cancer Institute, Center for Neuro-Oncology Dana-Farber Cancer Instiute

Lewis B. Silverman, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute and Children's Hospital Dana Faber Cancer Institute, Children's Hospital, Dept. of Pediatric Oncology Children's Hospital Boston Dana-Farber Cancer Institute

Karen Pet

AccelRx Research

Massimo Loda, MD

Suzanne Shusterman

Patrick Y. Wen, MD

Lewis B. Silverman, MD

Kay Kehoe, Coordinator

Jennifer Brown, MD

Rachel A. Freedman

Edwin P. Alyea, MD

F. Stephen Hodi, MD

Beth A. Overmoyer, MD, FACP